{"id":3905,"date":"2023-09-11T11:31:45","date_gmt":"2023-09-11T11:31:45","guid":{"rendered":"https:\/\/modafinil.pl\/?post_type=product&p=3905"},"modified":"2026-10-03T05:41:09","modified_gmt":"2026-10-03T05:41:09","slug":"5-htp-5-hydroxytryptophan","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/5-htp-5-hydroxytryptophan\/","title":{"rendered":"5-HTP \/ 5-Hydroxytryptophan (CAS 56-69-9) \u2014 Chemical Reagent 1000 mg, Purity \u2265 99.00%"},"content":{"rendered":"

2-Amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid<\/strong>, a white-to-off-white crystalline powder, purity \u2265 99.00%, 1000 mg package. Material intended solely for in vitro laboratory and analytical research<\/strong>. The product is not intended for consumption by humans or animals<\/strong>, is not a medicinal product, dietary supplement, food, or cosmetic.<\/p>\n

Three Different Entities That Must Not Be Confused<\/h2>\n

The same name “5-HTP” functions simultaneously in three independent contexts \u2014 chemical, pharmaceutical, and laboratory \u2014 and only separating them from the outset avoids drawing mistaken conclusions from one context to another:<\/p>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 medicinal product \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nWhat it concerns<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
5-hydroxytryptophan, CAS 56-69-9<\/th>\n		A chemical concept \u2014 a molecule with a defined structure. On its own it is neither a drug nor a reagent; its status is conferred by the form in which it was manufactured and authorized.<\/td>\nchemistry, substance registries<\/td>\n<\/tr>\n
Medicinal product
INN: oxitriptan<\/th>\n		Under the international nonproprietary name oxitriptan, the compound has been and still is registered as a pharmaceutical preparation in some European countries: a defined pharmaceutical form, manufacture under a pharmaceutical regime, registration dossier, and safety surveillance of use.<\/td>\npublished clinical studies in humans concerned this entity<\/strong><\/td>\n<\/tr>\n
Chemical reagent
the material offered here<\/th>\n		Material for laboratory and analytical work. It does not and cannot hold authorization for use in humans or animals<\/strong> \u2014 it has no pharmaceutical form and no medicinal-product documentation.<\/td>\nanalytics, chemistry, reference standards<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> The publications cited later on this page concern either the pharmaceutical preparation oxitriptan administered to patients under clinical conditions<\/strong> [6<\/a>][16<\/a>][17<\/a>], or analytical methods and studies in animals or microbiological strains<\/strong> under laboratory conditions. None of these works was carried out using the analytical reagent<\/strong>, and none of these results transfers to the material offered here. The reagent is not the form in which the substance was studied clinically, and it cannot be used that way.<\/p>\n

Reagent Identification Card<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 5-hydroxytryptophan<\/caption>\n
Systematic name (IUPAC)<\/th>\n2-amino-3-(5-hydroxy-1H-indol-3-yl)propanoic acid<\/td>\n<\/tr>\n
Common name<\/th>\n5-hydroxytryptophan (5-HTP)<\/td>\n<\/tr>\n
CAS number<\/th>\n56-69-9<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC11<\/sub>H12<\/sub>N2<\/sub>O3<\/sub><\/td>\n<\/tr>\n
Molar mass<\/th>\n220.22 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n220.0848 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nLDCYZAJDBXYCGN-UHFFFAOYSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nC1=CC2=C(C=C1O)C(=CN2)CC(C(=O)O)N<\/td>\n<\/tr>\n
PubChem CID<\/th>\n144<\/a><\/td>\n<\/tr>\n
Melting point<\/th>\n286 \u00b0C<\/td>\n<\/tr>\n
Form<\/th>\ncrystalline powder, white to off-white<\/td>\n<\/tr>\n
Purity<\/th>\n\u2265 99.00%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for consumption by humans or animals<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Molecular Lineage: From the Tryptophan Scaffold to a Neurotransmitter<\/h2>\n

5-Hydroxytryptophan is not a molecule designed in a medicinal chemistry laboratory \u2014 it is a natural biosynthetic intermediate<\/strong>, part of the same pathway by which living organisms convert the exogenous amino acid L-tryptophan into serotonin. The enzyme tryptophan hydroxylase introduces a hydroxyl group at position 5 of tryptophan’s indole ring \u2014 it is precisely this step that defines 5-HTP as an intermediate compound, not the starting point or the final product of the pathway. This biochemical lineage, however, does not translate into the status of the reagent offered here: the route by which the material sold for laboratory use is obtained is separate from the endogenous pathway and is discussed below.<\/p>\n

Commercial Plant Source: Griffonia simplicifolia<\/h3>\n

Although 5-HTP occurs in trace amounts in select foodstuffs, the main commercial source remains the seeds of Griffonia simplicifolia<\/strong> \u2014 a West African vine of the legume family. The chemical composition and seed-extraction methods of this plant have been the subject of separate analytical work: the chemical characterization and DNA fingerprinting of the plant material were described by Vigliante et al. [14<\/a>], and a comparison of different seed-extraction methodologies was carried out by Mannino et al. [18<\/a>]. The absorption kinetics of 5-HTP from Griffonia extract following oral administration have also been studied clinically [12<\/a>] \u2014 this work, however, concerns a plant-derived preparation given to study participants, not the analytical reagent, and is cited here solely as part of the molecule’s raw-material lineage.<\/p>\n

Alternative Route: Microbial Synthesis<\/h3>\n

Alongside plant extraction, a second, considerably younger route to obtaining 5-HTP has developed: biosynthesis in engineered microorganisms<\/strong>. Zeng and coworkers developed synthetic pathways leading to 5-HTP and serotonin from glucose in the bacterium Escherichia coli<\/em> [13<\/a>], using metabolic engineering instead of extraction from plant material. These are two entirely different routes to the same molecule \u2014 agricultural (seed extraction) and biotechnological (microbial fermentation) \u2014 which lead to an identical chemical product but differ in their profile of process-related impurities.<\/p>\n

Racemic Form versus Naturally Occurring Form<\/h3>\n

CAS number 56-69-9, assigned to this reagent in the PubChem registry (CID 144), refers to the racemic form, designated as (\u00b1)-5-hydroxytryptophan or DL-5-HTP<\/strong> \u2014 a mixture of both enantiomers at the stereogenic center on the \u03b1-carbon. This is an important distinction: the form biosynthesized endogenously in living organisms, and the one predominant in plant extracts, is the L-enantiomer, designated by a separate CAS number. The reagent offered here, CAS number 56-69-9, is the racemic form \u2014 it should not be equated without qualification with the single L-enantiomer, even though in commercial circulation the two terms are sometimes used interchangeably.<\/p>\n

Timeline<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Timeline: analytical methods and the regulatory context of the molecule<\/caption>\n
1962<\/th>\none of the first described methods for determining 5-hydroxytryptophan alongside serotonin [1<\/a>]<\/td>\n<\/tr>\n
1964<\/th>\na paper in Nature<\/em> on the regulation of 5-hydroxytryptophan decarboxylase in the rat pineal gland \u2014 one of the foundations of knowledge on the enzymatic conversion of 5-HTP to serotonin [2<\/a>]<\/td>\n<\/tr>\n
1976<\/th>\na method for determining 5-HTP and its metabolites in human plasma following administration [3<\/a>]<\/td>\n<\/tr>\n
1980\u20131981<\/th>\ndevelopment of sensitive HPLC methods with electrochemical and voltammetric detection for determining 5-HTP and its conversion products [4<\/a>][5<\/a>]<\/td>\n<\/tr>\n
1988<\/th>\nclinical publications on combining the oxitriptan preparation with classical antidepressants in European medical practice [6<\/a>]<\/td>\n<\/tr>\n
1989\u20131996<\/th>\nthe eosinophilia-myalgia syndrome (EMS) epidemic linked to L-tryptophan preparations; pathogenesis research also covers related 5-HTP preparations [8<\/a>][9<\/a>]<\/td>\n<\/tr>\n
2003<\/th>\nstructural characterization of a process-related impurity designated “Peak X” in commercial 5-HTP preparations linked to EMS cases [10<\/a>]<\/td>\n<\/tr>\n
2006<\/th>\na review of the pharmacology of serotonin-precursor administration [11<\/a>]<\/td>\n<\/tr>\n
2018\u20132019<\/th>\ndevelopment of a microbial synthesis route to 5-HTP in E. coli<\/em> [13<\/a>] and chemical characterization of the plant source Griffonia simplicifolia [14<\/a>]<\/td>\n<\/tr>\n
2020<\/th>\na comprehensive review of the natural occurrence, analytics, biosynthesis, biotechnology, physiology, and toxicology of 5-HTP [15<\/a>] and a meta-analysis of clinical studies on distinct types of depression [16<\/a>]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Research Centers and Context<\/h2>\n

The literature on 5-HTP is considerably more geographically dispersed than for molecules with a single parent research center \u2014 this reflects the fact that the substance itself is simultaneously the subject of clinical pharmacology, phytochemistry, and microbial biotechnology, pursued independently of one another. For a laboratory using this reagent, this means having to combine literature from several distinct disciplines.<\/p>\n